

**Community Health Network Oncology Research - Enrolling Clinical Trials**

9/4/2026

| <b>Multiple Disease Sites</b>     |                                                                                                                                                                                                                                                                                                                                                                                                               | <b>NCT #</b> | <b>Study Drug MOA</b>                            | <b>Indication/Population</b>                                                                                                                            | <b>Biomarker Target</b>       | <b>Sites Open</b>               |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------|
| AbbVie<br>M21-410                 | A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan                                                                                                                                                                                                                             | NCT05005403  | T-regs cell depleter                             | Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma                                                                                       | Various                       | North & South<br>(East on hold) |
| Amgen<br>20250004                 | A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 in Participants with Microsatellite Instability-High (MSI-H)/Deficient Mismatch Repair (dMMR) Solid Tumors                                                                                                                                                                                                               | NCT07403721  | WRN Inhibitor                                    | MSI-H/dMMR Solid Tumors                                                                                                                                 | Various                       | North & South<br>(East on hold) |
| Artios<br>ART0380C001             | A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors                                                                                                                                    | NCT04657068  | PROTAC degrader of KRAS G12D                     | Advanced or metastatic solid tumors w/ATM alterations                                                                                                   | ATM                           | North                           |
| Boehringer Ingelheim<br>1479-0009 | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour                                                                                                                                                                            | NCT06581432  | EGFR wild type sparing, selective HER2 inhibitor | HER2-mutated or overexpressed/amplified solid tumours                                                                                                   | HER2                          | North & South<br>(East on hold) |
| Boehringer Ingelheim<br>1479-0012 | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC) | NCT06324357  | EGFR wild type sparing, selective HER2 inhibitor | Advanced, unresectable HER2+ metastatic Breast Cancer & metastatic Colorectal Cancer                                                                    | HER2                          | North & South<br>(East pending) |
| DualityBio<br>DB-1311-201         | A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors                                                                                                                                                                                                                                                              | NCT05914116  | B7-H3 IgG1 ADC                                   | Advanced/metastatic solid tumors (Hepatocellular Carcinoma, Cervical Cancer, Melanoma, Head & Neck Squamous Cell Carcinomas, Non Small Cell Lung Cancer | B7H3, PD-L1, TROP2 and others | North & South<br>(East on hold) |

|                                              |                                                                                                                                                                                                                                                          |             |                               |                                                                                                                                                                       |                  |                              |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------------------|
| Exelixis XL092-002 (STELLAR-002)             | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors                                                                   | NCT05176483 | PD-L1 and PD-L2 inhibitor     | Unresectable advanced or metastatic solid tumors: Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma                                                               | Various          | North & South (East on hold) |
| GV20 Therapeutics GV20-0251-100              | An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies                                                                                                                                                    | NCT05669430 | IGSF8 antibody                | Advanced and/or refractory solid tumor malignancies (currently enrolling in Melanoma only)                                                                            | IGSF8 and others | North and South Only         |
| Hummingbird HMBD-501-101 (formerly Endeavor) | A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients with Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors                       | NCT06956690 | HER3-targeted ADC             | Advanced-stage, relapsed/refractory HER3-expressing solid tumors                                                                                                      | HER3             | North Only                   |
| InduPro Therapeutics IDP-001-101             | A Phase 1/2 Open-Label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors                                                                                                                                       | NCT07602842 | ADC targeting EGFR and CDCP-1 | mNCLC, other SQ tumors                                                                                                                                                | Various          | North & South (East on hold) |
| InSilico Medicine ISM3412-101                | A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors                      | NCT06414460 | MAT2A Inhibitor               | Locally advanced/metastatic solid tumors<br>Head & Neck Squamous Cell Carcinomas, Non Small Cell Lung Cancer, Bladder, Pancreatic Ductal Adenocarcinoma, Mesothelioma | Various          | North & South (East on hold) |
| KaliVir STEALTH-001                          | A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors                                                                                                                           | NCT06444815 | VET3-TGI                      | Advanced solid tumors IV cohort only                                                                                                                                  | Various          | North & South (East on hold) |
| Lilly J5J-OX-JZZA                            | Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor                                                                                                                                                                             | NCT06586515 | MAb targeting EGFR            | KRAS G12D-mutant solid tumors                                                                                                                                         | KRAS G12D        | North & South (East on hold) |
| Lilly J6D-MC-JSDA                            | A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors | NCT07046923 | ADC                           | Selected advanced solid tumors (currently enrolling in Non Small Cell Lung Cancer only)                                                                               | Various          | North & South (East on hold) |

|                                      |                                                                                                                                                                                                                                               |             |                                           |                                                                                                                                          |                 |                                 |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------------------------|
| MDA EXTEND-OP<br>(2024-0070)         | EXTENDING efficacy of systemic therapy with local consolidative therapy for OligoProgressive metastatic disease (EXTEND-OP): A randomized phase II basket trial                                                                               | NCT06367972 | N/A                                       | OligoProgressive metastatic disease                                                                                                      | Various         | North & South<br>(East on hold) |
| MDA<br>TAPUR                         | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study                                                                                                                                                                           | NCT02693535 | Various                                   | Various                                                                                                                                  | Various         | North & South<br>(East on hold) |
| Relay Therapeutics<br>RLY-2608-101   | Relay Therapeutics RLY-2608-101, A First-in-Human Study of Mutant-selective PI3K $\alpha$ Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PI3K $\alpha$ inhibitor                   | Unresectable or metastatic solid tumors                                                                                                  | PIK3CA          | North and South                 |
| Revolution Medicines<br>RMC-6291-101 | Phase 1b/2, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced KRAS G12C-mutated Solid Tumors                                                        | NCT06128551 | KRAS G12C(ON) and NRAS G12C(ON) Inhibitor | KRAS G12C-mutated solid tumors (currently enrolling in Non Small Cell Lung Cancer only)                                                  | Various         | North & South<br>(East on hold) |
| Seagen<br>SGNB6A-001                 | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors                                                                                                                                                                                           | NCT04389632 | ADC targeting integrin beta-6             | Dose expansion<br>Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma                                                      | Integrin beta-6 | North & South<br>(East on hold) |
| Volastra<br>VLS-1488-2201            | A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer                                                                                                                                                    | NCT05902988 | Oral KIF18A Inhibitor                     | Squamous Non Small Cell Lung Cancer, Head and Neck Squamous Cell Cancer, High Grade Serous Ovarian, Fallopian tube or Primary Peritoneal | KIF18A          | North and South Only            |

| Breast                               |                                                                                                                                                                                                                                                                                                                                                                                                               | NCT #       | Study Drug MOA                                   | Indication/Population                                 | Biomarker Target | Sites Open                      |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------|-------------------------------------------------------|------------------|---------------------------------|
| Boehringer<br>Ingelheim<br>1479-0012 | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC) | NCT06324357 | EGFR wild type sparing, selective HER2 inhibitor | Advanced, unresectable HER2+ metastatic Breast Cancer | HER2             | North & South<br>(East pending) |

|                                    |                                                                                                                                                                                                                                                                                                                                                                                          |             |                 |                                                                |                      |                                 |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------|----------------------------------------------------------------|----------------------|---------------------------------|
| MDA 2025-0779<br>(SAPHIRE-II)      | Shortening Adjuvant Photon and Proton Irradiation (SAPHIRE-II): A 4 cohort, randomized, phase II multi-center trial evaluating shorter schedules of adjuvant regional nodal irradiation among women and men with node-positive and high-risk node-negative invasive breast cancer                                                                                                        | NCT07076485 | RT              | Node-positive & high-risk node-negative invasive Breast Cancer | N/A                  | North & South<br>(East on hold) |
| NRG-BR009                          | A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) <25 (OFSET)                                                                                                                                                        | NCT05879926 | N/A             | Premenopausal women with pN0-1, HR+/HER2- Breast Cancer        | HR+/HER2-            | North & South<br>(East on hold) |
| Relay Therapeutics<br>RLY-2608-101 | A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer                                                                                                                                                                                     | NCT05216432 | PI3Kα inhibitor | HR+, HER2- locally advanced or metastatic Breast Cancer        | PIK3CA<br>HR+, HER2- | North and<br>South Only         |
| Relay Therapeutics<br>RLY-2608-102 | Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor | NCT06982521 | PI3Kα inhibitor | HR+/HER2- metastatic or locally advanced Breast Cancer         | PIK3CA<br>HR+, HER2- | North & South<br>(East on hold) |

| Gastrointestinal                  |                                                                                                                                                                                                                                                                            | NCT #       | Study Drug MOA                                      | Indication/Population                                                                  | Biomarker Target | Sites Open                      |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------------------------------------------|----------------------------------------------------------------------------------------|------------------|---------------------------------|
| Artios<br>ART0380C001             | A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors | NCT04657068 | PROTAC degrader of<br>KRAS G12D                     | Advanced or metastatic solid tumors w/ATM alterations<br><br>Colorectal and Pancreatic | ATM              | North Only                      |
| Boehringer Ingelheim<br>1479-0009 | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour                                         | NCT06581432 | EGFR wild type sparing, selective<br>HER2 inhibitor | Biliary Tract: HER2-mutated or overexpressed/amplified solid tumours                   | HER2             | North & South<br>(East on hold) |

|                                      |                                                                                                                                                                                                                                                                                                                                                                                                               |             |                                                  |                                                                                                                                                           |                               |                                 |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------|
| Boehringer Ingelheim<br>1479-0012    | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC) | NCT06324357 | EGFR wild type sparing, selective HER2 inhibitor | Metastatic Colorectal Cancer                                                                                                                              | HER2                          | North & South<br>(East pending) |
| DualityBio<br>DB-1311-201            | Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors                                                                                                                                                                                                                                                                                              | NCT05914116 | B7-H3 IgG1 ADC                                   | Advanced/metastatic solid tumors - Hepatocellular Carcinoma                                                                                               | B7H3, PD-L1, TROP2 and others | North & South<br>(East on hold) |
| Incyte<br>INCA033890-303             | A Randomized, Double-Blind, Phase 3 Study of Standard of Care Chemotherapy and Bevacizumab With or Without INCA33890 in First-Line Metastatic Colorectal Cancer                                                                                                                                                                                                                                               | NCT07284849 | G1 bispecific antibody                           | First-line metastatic Colorectal Cancer<br>(Pts eligible for first-line treatment with a checkpoint inhibitor or with a BRAF V600E mutation are excluded) | Various                       | North & South<br>(East on hold) |
| InSilico Medicine<br>ISM3412-101     | A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors                                                                                                                                                                           | NCT06414460 | MAT2A Inhibitor                                  | Pancreatic Ductal Adenocarcinoma                                                                                                                          | Various                       | North & South<br>(East on hold) |
| Janssen<br>89402638GIC1001           | A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer                                                                                                                                                                                                                                                                                                                                 | NCT06663319 | ADC                                              | Unresectable metastatic Colorectal Cancer                                                                                                                 | GUCY2C                        | North Only                      |
| Lilly<br>J5J-OX-JZZA                 | Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor                                                                                                                                                                                                                                                                                                                                  | NCT06586515 | MAb targeting EGFR                               | KRAS G12D-mutant solid tumors<br><br>Colorectal Cancer, Pancreatic Ductal Adenocarcinoma                                                                  | KRAS G12D                     | North & South<br>(East on hold) |
| MDA<br>TAPUR                         | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study                                                                                                                                                                                                                                                                                                                                           | NCT02693535 | Various                                          | Colorectal Cancer                                                                                                                                         | Various                       | North & South<br>(East on hold) |
| Revolution Medicines<br>RMC-6236-304 | RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)                                                                                                                                                                                      | NCT07252232 | RAS(ON) inhibitor                                | Resected Pancreatic Ductal Adenocarcinoma                                                                                                                 | B7H3, PD-L1, TROP2 and others | North & South<br>(East on hold) |

| Genitourinary                     |                                                                                                                                                                                                                                    | NCT #       | Study Drug MOA                                   | Indication/Population                                                                        | Biomarker Target | Sites Open                      |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------|----------------------------------------------------------------------------------------------|------------------|---------------------------------|
| Boehringer Ingelheim<br>1479-0009 | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour | NCT06581432 | EGFR wild type sparing, selective HER2 inhibitor | Urothelial: HER2-mutated or overexpressed/amplified solid tumours; Biliary Tract; Colorectal | HER2             | North & South<br>(East on hold) |

|                                  |                                                                                                                                                                                                                                     |             |                           |                                                                                               |         |                              |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------------------------|-----------------------------------------------------------------------------------------------|---------|------------------------------|
| Exelixis XL092-002 (STELLAR-002) | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors                                              | NCT05176483 | PD-L1 and PD-L2 inhibitor | Unresectable advanced or metastatic solid tumors: Urothelial, Clear Cell Renal Cell Carcinoma | Various | North & South (East on hold) |
| InSilico Medicine ISM3412-101    | A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors | NCT06414460 | MAT2A Inhibitor           | Bladder                                                                                       | Various | North & South (East on hold) |
| Pathos P300-02-001               | PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)                              | NCT06785636 | CBP/p300 inhibitor        | Metastatic Castration Resistant Prostate Cancer                                               | PSA     | North & South (East Pending) |

| Gyn                            |                                                                                                                                                                                                                                    | NCT #       | Study Drug MOA                                   | Indication/Population                                                                                                                        | Biomarker Target                                  | Sites Open                   |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|------------------------------|
| Boehringer Ingelheim 1479-0009 | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour | NCT06581432 | EGFR wild type sparing, selective HER2 inhibitor | Cervical: HER2-mutated or overexpressed/amplified solid tumours; Uterine                                                                     | HER2                                              | North & South (East on hold) |
| Daiichi DS6000-109 GOG-3096    | A Phase 2/3 randomized study of a Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers                  | NCT06161025 | CDH6-directed Antibody-drug Conjugate            | Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (at least 1, but no more than 3, prior systemic lines) | CDH6                                              | North & South (East on hold) |
| DualityBio DB-1311-201         | Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors                                                                                                                   | NCT05914116 | B7-H3 IgG1 ADC                                   | Advanced/metastatic solid tumors - Cervical Cancer                                                                                           | B7H3, PD-L1, TROP2 and others                     | North & South (East on hold) |
| Volastra VLS-1488-2201         | A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer                                                                                                                                         | NCT05902988 | Oral KIF18A Inhibitor                            | High Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer                                                                       | KIF18A                                            | North and South Only         |
| Zentalis ZN-c3-005 GOG-3066    | A Phase 2 Open-Label, Multicenter, Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (DENALI)                                                 | NCT05128825 | WEE-1 Inhibitor                                  | High Grade Serous Ovarian                                                                                                                    | CCNE1 amplification, cyclin E1 protein expression | North & South (East on hold) |

| Head and Neck                    |                                                                                                                                                                                                                                     | NCT #       | Study Drug MOA                | Indication/Population                                                   | Biomarker Target              | Sites Open                      |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------------------------|-------------------------------------------------------------------------|-------------------------------|---------------------------------|
| AbbVie<br>M21-410                | A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as a Single Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan                                                   | NCT05005403 | T-regs cell depleter          | Head and Neck Squamous Cell Carcinoma                                   | NA                            | North & South<br>(East on hold) |
| DualityBio<br>DB-1311-201        | Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors                                                                                                                    | NCT05914116 | B7-H3 IgG1 ADC                | Advanced/metastatic solid tumors - Head & Neck Squamous Cell Carcinomas | B7H3, PD-L1, TROP2 and others | North & South<br>(East on hold) |
| InSilico Medicine<br>ISM3412-101 | A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors | NCT06414460 | MAT2A Inhibitor               | Head and Neck Squamous Cell Carcinoma                                   | Various                       | North & South<br>(East on hold) |
| Seagen<br>SGNB6A-001             | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors                                                                                                                                                                                 | NCT04389632 | ADC targeting integrin beta-6 | Dose expansion:<br>Head and Neck Squamous Cell Carcinoma                | Integrin beta-6               | North & South<br>(East on hold) |
| Volastra<br>VLS-1488-2201        | A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer                                                                                                                                          | NCT05902988 | Oral KIF18A Inhibitor         | Head and Neck Squamous Cell Cancer                                      | KIF18A                        | North and<br>South Only         |

| Hematology         |                                                                                                                                                                                                                                                                                                                        | NCT #       | Study Drug MOA             | Indication/Population                         | Biomarker Target | Sites Open                                                                               |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------------------|-----------------------------------------------|------------------|------------------------------------------------------------------------------------------|
| MDA<br>TAPUR       | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study                                                                                                                                                                                                                                                    | NCT02693535 | Various                    | Multiple Myeloma, B Cell Non-Hodgkin Lymphoma | Various          | North & South<br>(East on hold)                                                          |
| Pfizer<br>C1071032 | MAGNETISMM-32: A Phase 3, Open-Label Study of Elranatamab Monotherapy Versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Bortezomib, Dexamethasone (PVD) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma Who Received Prior Anti-CD38 Directed Therapy | NCT06152575 | BsABS against BCMA and CD3 | Relapsed/refractory Multiple Myeloma          | Various          | North for C1D1 & C1D4 (if C1D1 is not tolerated well); open @ South for all other cycles |

| Lung                  |                                                                                                                                          | NCT #       | Study Drug MOA | Indication/Population      | Biomarker Target | Sites Open                      |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|----------------------------|------------------|---------------------------------|
| Ankyra<br>ANK-101-004 | A Phase 2, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination with PD1 in Participants with Advanced Non-Small Cell Lung Cancer | NCT07027514 | IL-12-ABP      | Non Small Cell Lung Cancer | Various          | North & South<br>(East on hold) |

|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                                                  |                                                                                             |                               |                                 |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------|---------------------------------|
| Boehringer Ingelheim<br>1479-0009    | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumour                                                                                                                                                                              | NCT06581432 | EGFR wild type sparing, selective HER2 inhibitor | Non Small Cell Lung Cancer                                                                  | HER2                          | North & South<br>(East on hold) |
| DualityBio<br>DB-1311-201            | Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors                                                                                                                                                                                                                                                                                                | NCT05914116 | B7-H3 IgG1 ADC                                   | Advanced/metastatic solid tumors - Non Small Cell Lung Cancer                               | B7H3, PD-L1, TROP2 and others | North & South<br>(East on hold) |
| InSilico Medicine<br>ISM3412-101     | A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants with Locally Advanced/Metastatic Solid Tumors                                                                                                                                                                             | NCT06414460 | MAT2A Inhibitor                                  | Non Small Cell Lung Cancer                                                                  | Various                       | North & South<br>(East on hold) |
| Lilly<br>J3M-MC-JZQB                 | SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression $\geq 50\%$ or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression | NCT06119581 | KRAS G12C Inhibitor                              | KRAS G12C-mutant, locally advanced or metastatic Non Small Cell Lung Cancer                 | KRAS G12C-Mutant              | North and South Only            |
| Lilly<br>J5J-OX-JZZA                 | Phase 1a/1b Study of LY3962673 in Patients with KRAS G12D-Mutant Solid Tumor                                                                                                                                                                                                                                                                                                                                    | NCT06586515 | MAB targeting EGFR                               | KRAS G12D-mutant solid tumors: Non Small Cell Lung Cancer                                   | KRAS G12D                     | North & South<br>(East on hold) |
| Revolution Medicines<br>RMC-6236-301 | RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Unresectable or Metastatic NSCLC Harboring RAS Mutations                                                                                                                                                                                                                        | NCT06881784 | RAS(ON) multi-selective inhibitor                | Previously treated unresectable or metastatic Non Small Cell Lung Cancer with RAS mutations | Various                       | North & South<br>(East on hold) |
| Seagen<br>SGNB6A-001                 | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors                                                                                                                                                                                                                                                                                                                                                             | NCT04389632 | ADC targeting integrin beta-6                    | Dose expansion: Non Small Cell Lung Cancer                                                  | Integrin beta-6               | North & South<br>(East on hold) |
| Volastra<br>VLS-1488-2201            | A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer                                                                                                                                                                                                                                                                                                                      | NCT05902988 | Oral KIF18A Inhibitor                            | Dose expansion: sq-Non Small Cell Lung Cancer                                               | KIF18A                        | North and South Only            |



| Melanoma                           |                                                                                                                      | NCT #       | Study Drug MOA | Indication/Population                       | Biomarker Target              | Sites Open                   |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------|----------------|---------------------------------------------|-------------------------------|------------------------------|
| DualityBio<br>DB-1311-201          | Phase II clinical study for DB-1311 in Combination with BNT327 or DB1305 for patients with Advanced Solid Tumors     | NCT05914116 | B7-H3 IgG1 ADC | Advanced/metastatic solid tumors - Melanoma | B7H3, PD-L1, TROP2 and others | North & South (East on hold) |
| GV20 Therapeutics<br>GV20-0251-100 | GV20-0251-100, An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies | NCT05669430 | IGSF8 antibody | Cutaneous Melanoma                          | IGSF8 and others              | North and South Only         |